Artiva Biotherapeutics (NASDAQ:ARTV) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Several other brokerages also recently commented on ARTV. Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday. Cantor Fitzgerald dropped their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Stock Down 8.8 %

Shares of NASDAQ ARTV opened at $3.64 on Wednesday. The firm’s fifty day moving average is $4.84 and its 200 day moving average is $9.33. Artiva Biotherapeutics has a 52 week low of $3.37 and a 52 week high of $17.31.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ARTV. Charles Schwab Investment Management Inc. bought a new position in Artiva Biotherapeutics in the 3rd quarter worth about $623,000. BNP Paribas Financial Markets purchased a new position in Artiva Biotherapeutics in the third quarter worth about $42,000. MetLife Investment Management LLC bought a new position in shares of Artiva Biotherapeutics in the third quarter worth approximately $135,000. Acuta Capital Partners LLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $680,000. Finally, RTW Investments LP bought a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $2,300,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.